AAOS 2025: Efficacy of Autologous Dermal Fibroblast Injection - Retear Rate Post Rotator Cuff Repair
Efficacy of autologous dermal fibroblast injection in reducing retear rate after arthroscopic rotator cuff repair: a prospective randomized controlled clinical trial
Seventy-two patients with full-thickness rotator cuff tears were randomized to receive either arthroscopic rotator cuff repair (ARCR) with intraoperative injection of autologous dermal fibroblasts (ADFs) (n=35) or ARCR alone (n=37). The primary outcome of interest was the retear rate assessed by MRI at 6 months postoperatively. Secondary outcomes included range of motion, ASES score, Constant score, and simple shoulder test (SST), evaluated at baseline, 6 months, and 12 months. Overall, the results of the study revealed a significantly lower retear rate in the ADF group compared to the control group (2.9% vs. 16.2%, p=0.012), although there were no significant differences in clinical outcomes between groups at follow-up. These findings suggest that ADF injection may enhance tendon healing after ARCR without compromising clinical recovery.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics